BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

In Collaboration With MRC Technology, Groundbreaking New Software From IDBS Predicts Potential New Malaria Therapeutics At Fraction Of Usual Time And Cost


10/19/2005 5:10:06 PM

IDBS, provider of drug discovery software, and MRC Technology (MRCT), the technology transfer company associated with the UK’s Medical Research Council, today announced that good progress has been made in their malaria research collaboration as a result of adopting model-based drug discovery. This new approach to research has enabled extremely efficient use of a limited budget. Using PredictionBase, a new suite of software tools from IDBS for modelling the suitability of compounds as drugs, MRCT researchers were able to predict with 90% accuracy both the active and inactive compounds against a new malarial target. Having proved the effectiveness of advanced in silico algorithms for the PfSUB-1 assay, which measures inhibition of a protease important in the blood stage of the malarial parasite, MRCT and IDBS will extend the collaboration. The in silico model generated by PredictionBase will be further refined, to deliver more compounds exhibiting the ADME/tox, efficacy and safety profiles of potential malarial drugs – without the traditional time and expense of large-scale diversity screening.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES